PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $25,864,000 | -38.4% | 842,478 | +34.6% | 0.01% | -44.4% |
Q3 2016 | $41,975,000 | +134.0% | 626,024 | +4.0% | 0.01% | +125.0% |
Q2 2016 | $17,936,000 | +164.5% | 602,071 | +160.7% | 0.00% | +100.0% |
Q1 2016 | $6,782,000 | -64.3% | 230,920 | -4.7% | 0.00% | -50.0% |
Q4 2015 | $19,006,000 | +10.9% | 242,424 | +6.6% | 0.00% | 0.0% |
Q3 2015 | $17,133,000 | -35.9% | 227,353 | -0.7% | 0.00% | -33.3% |
Q2 2015 | $26,741,000 | -82.6% | 229,042 | -64.8% | 0.01% | -83.8% |
Q1 2015 | $153,457,000 | +34.4% | 649,940 | +7.8% | 0.04% | +32.1% |
Q4 2014 | $114,145,000 | -10.8% | 603,082 | +12.4% | 0.03% | -22.2% |
Q3 2014 | $127,994,000 | +266.4% | 536,506 | +1.4% | 0.04% | +260.0% |
Q2 2014 | $34,935,000 | -42.3% | 529,311 | -9.0% | 0.01% | -44.4% |
Q1 2014 | $60,582,000 | +7.6% | 581,739 | +7.0% | 0.02% | +5.9% |
Q4 2013 | $56,278,000 | +84.0% | 543,593 | -4.7% | 0.02% | +70.0% |
Q3 2013 | $30,593,000 | +36.8% | 570,135 | +13.1% | 0.01% | +25.0% |
Q2 2013 | $22,367,000 | – | 504,098 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 207,500 | $21,609,000 | 4.97% |
WEATHERBIE CAPITAL, LLC | 250,296 | $26,066,000 | 2.47% |
Redmile Group, LLC | 172,092 | $17,922,000 | 2.14% |
Tekla Capital Management LLC | 185,820 | $19,351,000 | 1.93% |
Iguana Healthcare Management, LLC | 35,000 | $3,645,000 | 1.68% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $592,210,000 | 1.62% |
Atika Capital Management LLC | 11,350 | $1,182,000 | 1.01% |
Eventide Asset Management | 44,900 | $4,676,000 | 0.73% |
Ghost Tree Capital, LLC | 11,330 | $1,180,000 | 0.70% |
BB BIOTECH AG | 117,991 | $12,288,000 | 0.63% |